Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer

被引:0
作者
Vincenza Conteduca
Simon J. Crabb
Emanuela Scarpi
Catherine Hanna
Francesca Maines
Helen Joyce
Paolo Fabbri
Lisa Derosa
Francesco Massari
Cristian Lolli
Sunnya Zarif
Robert J. Jones
Orazio Caffo
Tony Elliott
Ugo De Giorgi
机构
[1] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS,Department of Medical Oncology
[2] University of Southampton,Cancer Sciences Unit
[3] Beatson West of Scotland Cancer Centre,Medical Oncology Department
[4] Santa Chiara Hospital,Oncology Unit
[5] Christie Hospital,Medical Oncology Department
[6] Cervesi Hospital,Medical Oncology
[7] Santa Chiara Hospital,Institute of Cancer Sciences
[8] Azienda Ospedaliera Universitaria Integrata,undefined
[9] University of Glasgow,undefined
来源
Molecular Diagnosis & Therapy | 2016年 / 20卷
关键词
Overall Survival; Prostate Specific Antigen; Abiraterone; Prostate Specific Antigen Level; Enzalutamide;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:255 / 263
页数:8
相关论文
共 157 条
[1]  
Stamey TA(1987)Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 909-916
[2]  
Yang N(2010)Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes Urology. 76 1072-1076
[3]  
Hay AR(2014)Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer J Clin Oncol 32 671-677
[4]  
McNeal JE(2015)Integrative clinical genomics of advanced prostate cancer Cell 161 1215-1228
[5]  
Freiha FS(2014)Tumor clone dynamics in lethal prostate cancer Sci Transl Med 6 254ra125-8261
[6]  
Redwine E(2005)Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J Clin Oncol 23 8253-790
[7]  
Carvalhal GF(2009)Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 787-1197
[8]  
Daudi SN(2012)Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 1187-433
[9]  
Kan D(2014)Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 424-230
[10]  
Mondo D(2015)Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial Eur Urol 67 223-1159